MA46901A - Agents psychotropes et leurs utilisations - Google Patents

Agents psychotropes et leurs utilisations

Info

Publication number
MA46901A
MA46901A MA046901A MA46901A MA46901A MA 46901 A MA46901 A MA 46901A MA 046901 A MA046901 A MA 046901A MA 46901 A MA46901 A MA 46901A MA 46901 A MA46901 A MA 46901A
Authority
MA
Morocco
Prior art keywords
psychotropic agents
psychotropic
agents
Prior art date
Application number
MA046901A
Other languages
English (en)
Inventor
Vincent T Grattan
Zachary Prensky
Andrew R Vaino
Original Assignee
Lb Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lb Pharmaceuticals Inc filed Critical Lb Pharmaceuticals Inc
Publication of MA46901A publication Critical patent/MA46901A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA046901A 2016-11-28 2017-11-28 Agents psychotropes et leurs utilisations MA46901A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427062P 2016-11-28 2016-11-28
US201762508263P 2017-05-18 2017-05-18

Publications (1)

Publication Number Publication Date
MA46901A true MA46901A (fr) 2019-10-02

Family

ID=62195369

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046901A MA46901A (fr) 2016-11-28 2017-11-28 Agents psychotropes et leurs utilisations

Country Status (12)

Country Link
US (8) US10259786B2 (fr)
EP (1) EP3544606B1 (fr)
JP (1) JP6968899B2 (fr)
KR (1) KR102274338B1 (fr)
CN (2) CN110248655B (fr)
AU (3) AU2017364899B2 (fr)
ES (1) ES2908949T3 (fr)
MA (1) MA46901A (fr)
MY (2) MY205036A (fr)
NZ (1) NZ753671A (fr)
SG (1) SG10201914135TA (fr)
WO (1) WO2018098497A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY205036A (en) 2016-11-28 2024-09-28 Lb Pharmaceuticals Inc Psychotropic agents and uses thereof
US11377421B2 (en) 2016-11-28 2022-07-05 Lb Pharmaceuticals Inc. Psychotropic agents and uses thereof
CN121668158A (zh) * 2017-05-18 2026-03-17 Lb制药公司 精神药剂及其用途
US10369134B2 (en) 2017-12-05 2019-08-06 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
CN110790693A (zh) * 2018-08-02 2020-02-14 北京万全德众医药生物技术有限公司 一种(s)(-)-氨磺必利的制备方法
EP3870292A4 (fr) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York Combinaison d'un inhibiteur de réabsorption spécifique de la sérotonine et d'un agoniste partiel du récepteur de la sérotonine 1a pour réduire la dyskinésie induite par l-dopa
WO2020247627A1 (fr) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Formulations à libération modifiée et utilisations associées
JP2024519065A (ja) * 2021-05-18 2024-05-08 エルビー・ファーマシューティカルズ・インコーポレイテッド 向精神薬とその用途
TW202529747A (zh) * 2023-10-06 2025-08-01 美商Lb製藥股份有限公司 抗精神病藥劑之用途
KR20250179850A (ko) 2024-06-24 2025-12-31 이선영 세탁기 건조기 일체형

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
US4210660A (en) 1978-12-20 1980-07-01 Yamanouchi Pharmaceutical Co., Ltd. Benzamide derivatives
US4772630A (en) * 1984-11-23 1988-09-20 Ciba-Geigy Corp. Benzamides and their salts
FR2678266A1 (fr) * 1991-06-28 1992-12-31 Delagrange Laboratoires Nouveaux derives de 2-hydroxy 4-amino 5-ethylsulfonyl benzamide utiles comme anxiolytiques.
CA2187429A1 (fr) * 1994-04-28 1995-11-09 Junya Ohmori Derive de n-(3-pyrrolidinyl)benzamide
US5606482A (en) * 1995-04-14 1997-02-25 Lucent Technologies Inc. Solid state circuit breaker
FR2753376B1 (fr) 1996-09-18 1998-10-16 Synthelabo Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques
US6169094B1 (en) 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
US20050203130A1 (en) 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CN101636182B (zh) 2006-10-25 2013-01-16 雷蒙特亚特特拉维夫大学有限公司 具有谷氨酸nmda活性的新型精神病治疗剂
US20080108602A1 (en) 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US20100105755A1 (en) 2008-09-12 2010-04-29 Auspex Pharmaceuticals, Inc. Substituted benzamide modulators of dopamine receptor
WO2012062697A1 (fr) 2010-11-08 2012-05-18 Novartis Ag Polythérapie pour diabète de type 1
WO2013040164A1 (fr) * 2011-09-13 2013-03-21 Biomed Valley Discoveries, Inc. Compositions et méthodes pour le traitement des troubles métaboliques
CN102807516A (zh) * 2012-08-16 2012-12-05 四川省百草生物药业有限公司 氨磺必利的中间体及利用该中间体制备氨磺必利的方法
RU2018130270A (ru) 2016-01-22 2020-02-25 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Способ получения 4-алкокси-3-ацетоксипиколиновых кислот
MY205036A (en) * 2016-11-28 2024-09-28 Lb Pharmaceuticals Inc Psychotropic agents and uses thereof
CN121668158A (zh) 2017-05-18 2026-03-17 Lb制药公司 精神药剂及其用途
US10369134B2 (en) 2017-12-05 2019-08-06 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof

Also Published As

Publication number Publication date
US20220144770A1 (en) 2022-05-12
US20240158347A1 (en) 2024-05-16
EP3544606A4 (fr) 2019-12-18
US20240150283A1 (en) 2024-05-09
US11713295B2 (en) 2023-08-01
EP3544606A1 (fr) 2019-10-02
US12060327B2 (en) 2024-08-13
US20200055818A1 (en) 2020-02-20
AU2023241329A1 (en) 2023-10-26
US10259786B2 (en) 2019-04-16
ES2908949T3 (es) 2022-05-04
US20200079734A1 (en) 2020-03-12
BR112019010127A2 (pt) 2019-08-20
US11040943B2 (en) 2021-06-22
US20180170868A1 (en) 2018-06-21
JP6968899B2 (ja) 2021-11-17
AU2025267332A1 (en) 2025-12-04
MY210249A (en) 2025-09-04
KR102274338B1 (ko) 2021-07-06
NZ753671A (en) 2025-10-31
US20200002277A1 (en) 2020-01-02
AU2017364899A1 (en) 2019-05-30
CN110248655B (zh) 2023-07-07
US20180155282A1 (en) 2018-06-07
CN110248655A (zh) 2019-09-17
AU2017364899B2 (en) 2023-07-06
EP3544606B1 (fr) 2022-03-09
JP2019535837A (ja) 2019-12-12
SG10201914135TA (en) 2020-02-27
KR20190086536A (ko) 2019-07-22
CN111233731A (zh) 2020-06-05
US10689338B2 (en) 2020-06-23
CN111233731B (zh) 2021-05-14
US10167256B2 (en) 2019-01-01
WO2018098497A1 (fr) 2018-05-31
MY205036A (en) 2024-09-28

Similar Documents

Publication Publication Date Title
FR25C1020I1 (fr) Anticorps thérapeutiques et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
EP3661563A4 (fr) Nanomatériaux biomimétiques et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
EP3471727A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
EP3472129A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
MA53145A (fr) Agents de liaison cd123 et leurs utilisations
EP3349802A4 (fr) Dendrimères lipocationiques et leurs utilisations
EP3334706A4 (fr) Pillararènes et utilisations de ceux-ci
EP3283516A4 (fr) Anticorps anti-pacap et leurs utilisations
MA46901A (fr) Agents psychotropes et leurs utilisations
EP3337486A4 (fr) Composés deutérés et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
MA43821A (fr) Pyrimidines et variantes de celles-ci, et leurs utilisations
EP3370528A4 (fr) Compositions probiotiques et leurs utilisations
EP3471726A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP3538261A4 (fr) Catalyseurs en pérovskite et leurs utilisations
EP3347021A4 (fr) Cyano-thiénotriazoloazépines et leurs utilisations
EP3364958A4 (fr) Modulateurs d'interaction sestrine-gator2 et leurs utilisations
EP3347020A4 (fr) Acétamide thiénotriazoldiazépines et leurs utilisations